Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki

News provided by

Sep 10, 2024, 03:30 ET

Dr. Kariuki brings a wealth of experience in ADCs, across corporate strategy, finance and operations
Advancement of Pheon's differentiated ADC pipeline, accelerating first program, PHN-010, into clinical development this year

LONDON, Sept. 10, 2024 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the appointment of accomplished biotech executive, Enoch Kariuki, Pharm.D., to its Board of Directors as an independent, non-executive director.

Dr. Kariuki possesses extensive strategic, operational, and financial life sciences experience. He most recently served as the Chief Executive Officer of Lengo Therapeutics, which was acquired by Blueprint Medicines. Prior to Lengo Therapeutics, he served as the Chief Financial Officer of VelosBio, which was acquired by Merck, where he led all finance-related and investor relations functions. Prior to that, he was Senior Vice President, Corporate Development at Synthorx, which was acquired by Sanofi. In addition, Dr. Kariuki previously served as Board Director and Audit Chair of Imago Biosciences which was acquired by Merck, and ProfoundBio which was acquired by Genmab.

Cyrus Mozayeni, MD, Chief Executive Officer of Pheon, said: "Dr. Kariuki joins Pheon at a pivotal stage of growth, as we advance into clinical development with PHN-010, our lead ADC program targeting patients with advanced solid tumors. His decision to join Pheon's board reflects his belief in our innovative pipeline and our team's track record in targeted oncology therapies and ADCs. Dr. Kariuki brings a wealth of executive leadership experience and knowledge in ADCs, which further strengthens our board as we transition into a clinical stage company and beyond."

Dr. Kariuki's appointment follows the completion of a $120m Series B financing round earlier this year to advance Pheon's three first-in-class ADC assets through clinical proof of concept. The company's first program, PHN-010, will enter Phase 1 clinical trials in 2024, targeting an undisclosed novel target which is overexpressed in a wide range of solid tumors.

Enoch Kariuki, Pharm.D., newly appointed Board Member of Pheon, commented: "There have been tremendous advances in the evolving field of ADCs and through my previous experience in advising and investing in life sciences companies, I have become familiar with Pheon's innovative work. I am excited to contribute to Pheon's development of next generation ADCs and to help advance these transformative therapies for the benefit of patients in need."

Dr. Kariuki currently serves on the board of Zentalis Pharmaceuticals and is President of Endeavor BioMedicines. Earlier in his career, Dr. Kariuki was Vice President at H.I.G. Capital, a private equity firm managing over $60 billion in assets, where he invested in and served on the boards of multiple life sciences companies. His other previous positions include Senior Associate at Leerink Partners and Associate Director at UBS Investment Bank, where he advised healthcare companies on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.

Dr. Kariuki completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol-Myers Squibb and was a Pharmacist at CVS Caremark. He holds an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University.

About Pheon Therapeutics

Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of ADCs, based on novel targets and novel linker payloads, to treat solid tumors. Pheon's lead program is a first-in-class ADC program against a novel target that is highly overexpressed in solid tumors across a broad range of hard-to-treat cancer types. Pheon is backed by expert, specialist healthcare investors TCGX, Atlas Venture, BVF Partners, Brandon Capital, Forbion, Lightspeed Venture Partners (Lightspeed), Perceptive Advisors, and Research Corporation Technologies. Pheon has a world class, proven leadership team that brings together the best of ADC engineering, clinical and managerial expertise, and track record. For further information, please visit www.pheontx.com

SOURCE Pheon Therapeutics